The microtubule (MT) represents a highly validated target for therapy. Insights into the complex nature of the dynamic microtubule
physiology will provide the basis for developing novel microtubule targeting agents with enhanced efficacy and minimised toxicity.
In this article, with an emphasis on translational applications, we have summarised relevant aspects of tubulin physiology in the context
of developing MT binding agents as therapeutic agents. Case studies were included to illustrate therapeutic developments in prostate
cancer and current strategies to discover novel agents or targets for therapy.
Keywords: Microtubule (MT), microtubule associated proteins (MAPs), microtubule targeting agents (MTAs), chemotherapy, tubulin heterodimers, polymerases, angiogenesis, neutropenia, p21-activated kinase 6 (PAK6), prostate cancer
Rights & PermissionsPrintExport